<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Sequenom Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/sequenom-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(LMNX) Luminex Wraps Up EraGen Buy</title>
		<link>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787</link>
		<comments>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:33:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77787</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has completed its previously-announced acquisition of privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The companies struck a definitive agreement on June 21. Madison, Wisconsin-based EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. The acquisition provides Luminex a highly complementary portfolio of molecular diagnostic tests based on the MultiCode platform. Besides, it enables the company to tap new markets leveraging EraGen’s innovative technologies. Luminex envisions the acquisition to add between $5 million and $7 million to its sales for 2011. Moreover, the company expects the transaction to dilute its earnings (on a reported basis) in 2011 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Gets EraGen for $34M</title>
		<link>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193</link>
		<comments>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:02:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77193</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has forged a definitive agreement to buy Madison, Wisconsin-based privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The transaction, which is subject to the clearance of EraGen shareholders and other customary conditions, is expected to complete within the next few weeks. EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. EraGen received, in May 2010, the approval of the U.S. Food and Drug Administration (“FDA”) for its MultiCode-RTx HSV 1&#38;2 Kit. It is the first FDA-approved molecular test for the herpes simplex virus (“HSV”). The acquisition will provide Luminex a highly complementary portfolio of molecular diagnostic tests based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Tops Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741</link>
		<comments>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741#comments</comments>
		<pubDate>Thu, 12 May 2011 00:51:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73741</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and exceeding the year-ago earnings of 5 cents. Profit more than doubled year over year to roughly $4.5 million owing to higher sales. Revenues shot up 30% year over year to $43.3 million, ahead of the Zacks Consensus Estimate of $40 million. The growth was led by solid consumables and assay sales. Consumable sales rocketed 53% to a record $15 million, buoyed by healthy demand from the company’s major partners. System revenues climbed 15% to $7.7 million, helped by healthy shipments of multiplexing analyzers. The Texas-based company shipped 197 analyzers (including 38 MAGPIX systems) in the quarter, flat year over year. Royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Affymetrix Analyst Initiates Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708</link>
		<comments>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708#comments</comments>
		<pubDate>Sun, 17 Apr 2011 18:39:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[CBMX]]></category>
		<category><![CDATA[CombiMatrix Corporation]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71708</guid>
		<description><![CDATA[We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit surged 42% year over year as lower costs more than offset a decline in sales. California-based Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies primarily used in the field of genetic research. Affymetrix has expertise in gene expression monitoring arrays, which are used to identify correlations between genes, determine their biological functions, and identify patterns that enable more accurate disease classification. It has a dominant position in the gene expression market and enjoys a recurring ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Wins MDEA</title>
		<link>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348</link>
		<comments>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71348</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized by the leading business-to-business media company UBM Canon, is a premier awards program which recognizes the achievements of medical devices manufacturers. MAGPIX was recognized in the “In Vitro Diagnostics” category of the award, through a comprehensive review by a multi-disciplinary jury panel, for its innovative design and contribution. The award will be presented at a ceremony on June 8, 2011, at the Jacob K. Javits Convention Center in New York City. The MAGPIX system (launched in July 2010) leverages Luminex’s proprietary open-architecture xMAP technology and is capable of producing up to 50 tests on a single sample. The versatile multiplexing platform can be used to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Earns FDA Approval for New Diagnostic Test</title>
		<link>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911</link>
		<comments>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911#comments</comments>
		<pubDate>Thu, 18 Nov 2010 19:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59911</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an individual&#8217;s response to drugs. The test, dubbed the xTAG CYP2D6 Kit, has been designed to bring in the personalized medicine approach by helping physicians to identify and manage patients for whom they may prescribe therapies which are metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. The xTAG CYP2D6 Kit will be marketed throughout the U.S. through Luminex Molecular Diagnostics (“LMD”), a unit of the company’s Assay segment. The CYP2D6 enzyme is involved in the metabolism of many prescription drugs. A segment of the population may carry a slow-acting or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442</link>
		<comments>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:50:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59442</guid>
		<description><![CDATA[We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted loss per share of 2 cents missed the Zacks Consensus Estimate of earnings of 4 cents. Losses swelled 19% year over year as revenue growth was offset by higher costs and tax. Top line improved on solid consumables and assay sales, but missed the Zacks Consensus Estimate. Annualized decline in the shipments of analytical instruments contributed to lower system sales in the quarter.The company has narrowed its revenue forecast for fiscal 2010. Luminex develops, manufactures and markets proprietary biological testing technologies, which have applications across the life sciences industry. The company’s proprietary open-architecture xMAP technology enables fast, cost-effective and accurate conduct and analysis of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199</link>
		<comments>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:15:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25199</guid>
		<description><![CDATA[Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These positive factors should drive growth in the coming quarters. Additionally, Luminex has an interesting pipeline. Should the pipeline develop successfully, the company can look at further growth. We are pleased with the company&#8217;s broad product portfolio. Luminex’s instrument base consists of the Luminex 100 (LX100), Luminex 200 (LX200) and FlexMap 3D systems. The Luminex 100 and 200 are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 bioassays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. By combining small diode lasers with digital ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Posts Loss</title>
		<link>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552</link>
		<comments>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:36:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21552</guid>
		<description><![CDATA[Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. The loss in the quarter was attributable to the higher operating expenses which more than offset the increase in revenues. Total revenues for the reported quarter came in at $29.1 million as against $28.9 million in the year-ago period, up 1%. As per segments, revenues from the Technology segment came in at 22 million as against $22.6 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $7.1 million, up 12% over the comparable quarter of 2008. Total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

